TB-500 has been studied across a wide range of research areas involving tissue repair, inflammation, immune response, and recovery-related biological processes.
In a 2009 study using 0.01% TB-500 eye drops, researchers observed faster healing after eye surgery in diabetic patients. This group was especially important to study because diabetes is commonly associated with delayed wound healing and a higher risk of eye-related complications, including diabetic retinopathy. The study reported no serious side effects, although headache, dizziness, and insomnia occurred more often in the TB-500 group than in the control group. Researchers also found that diabetic retinopathic corneas expressed lower levels of naturally occurring TB-500 compared with normal corneas, suggesting that reduced endogenous TB-500 may contribute to slower healing after eye injury or surgery. TB-500 eye drops have also been studied in chronic dry eye, where participants showed symptom improvement with rare and minimal complications. [5] [6]
TB-500 has also been evaluated in research involving chronic hepatitis B combined with nonalcoholic fatty liver disease. While TB-500 levels did not appear to correlate with hepatitis B viral levels or liver markers such as AST, ALT, or triglycerides, researchers observed an inverse relationship with inflammation and fibrosis scores. In simpler terms, lower TB-500 levels were associated with more severe inflammation and fibrosis. These findings suggest that TB-500 may have relevance in certain liver-related research models. [7]
A 2010 human safety and tolerance study evaluated intravenous TB-500 doses ranging from 42 mg to 1260 mg daily for 14 days. The study reported no treatment-related adverse effects and no evidence of dose-related toxicity within the range studied. [8]
TB-500 has also been studied in immune-response research. In one study, healthy volunteers were intentionally exposed to rhinovirus, a common cold virus, while blood markers were monitored over five days. By the fifth day, serum cortisol, thymosin alpha-1, and TB-500 levels increased. Several immune cell populations also increased, including T-lymphocytes, cytotoxic/suppressor cells, and natural killer cells. These findings suggest a possible relationship between thymosin-related peptides and the body’s immune response following respiratory virus exposure. [9]
Kidney disease research has also explored TB-500. In mouse studies, TB-500 levels did not appear to affect healthy kidney tissue. However, in mice with existing kidney disease, lower TB-500 levels were associated with worsening disease progression. Researchers suggested that naturally occurring TB-500 may help protect kidney tissue and slow disease-related damage in certain models. [10]
TB-500 has been widely examined in wound-healing research. Studies involving both animal and human subjects have explored its role in burns, diabetic ulcers, pressure ulcers, stasis ulcers, epidermolysis-related wounds, wounds in elderly subjects, and other tissue injuries. Research suggests that TB-500 may support wound healing by promoting angiogenesis, helping regulate inflammation, and increasing platelet activity at wound sites. [11]
A 2015 meta-analysis reviewed broader TB-500 research and highlighted its potential involvement in tissue repair and regeneration across multiple biological systems. Areas of interest included cardiac repair after myocardial injury, neurological recovery after stroke or trauma, kidney and liver disease models, spinal cord repair, bone and ligament injury, aging-related decline, and viral-response pathways. [12]
Bone-healing studies have also investigated TB-500. In mouse fracture models, TB-500-treated subjects developed stronger healed fractures compared with untreated controls. Treated mice showed a 41% increase in peak force to failure, and healed fractures were 25% stiffer than those in untreated mice. Imaging performed 21 days after fracture showed improvement of up to 26% compared with untreated subjects. Researchers also observed smaller callus formation and increased trabecular bone area, suggesting faster and more organized bone repair. [13]
TB-500 has also been studied in spinal cord injury models. In a 2014 rat study, TB-500 was administered either 30 minutes, 3 days, or 5 days after mild compression-induced spinal cord injury. Treated rats showed notable improvement in locomotor and behavioral assessments. Researchers also observed reduced inflammatory cytokines, smaller scar formation, and myelin protein levels that were 57.8% higher than the control group. These findings suggest that TB-500 remains an area of interest in spinal cord injury and repair-related research. [14]
In traumatic brain injury research, TB-500 has been studied in rat models. While no animal model perfectly replicates human head injury, rats are commonly used because their neurological and behavioral responses are well characterized. Research suggests that TB-500 may have both neuroprotective and neurorestorative effects, including support for blood vessel formation, new brain cell development, and new neural connections following injury. [15]
TB-500 has also been investigated in models of multiple sclerosis. In a 2016 study by Zhang et al., TB-500 administration increased the generation of new oligodendrocytes and reduced axonal damage compared with controls. The newly generated oligodendrocytes contributed to remyelination of axons, which was associated with functional improvement in the study model. [16]
